Clinical Lymphoma Myeloma and Leukemia This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma
Black and Latino/Hispanic populations are disproportionately impacted by multiple myeloma (MM) in the United States and are underrepresented in many clinical trials. The Multiple Myeloma Research Foundation sponsored a one-day workshop of 46 experts spanning the ecosystem of MM research and care, including government, academia, non-profits, pharma/biotech, community partners, and retail pharmacy. Specific, tangible steps to overcome the well-documented barriers to improving the diversity and inclusivity of clinical trials were discussed, including broadening inclusion/exclusion criteria, reducing the financial and other bu...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 14, 2023 Category: Hematology Authors: Monique Hartley-Brown, Craig E. Cole, Pamela Price, Michael Andreini, George Mulligan, Anne Quinn Young, Hearn Jay Cho Tags: Perspective article Source Type: research

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study
Daratumumab, lenalidomide, dexamethasone (DRd) and bortezomib, lenalidomide, dexamethasone (VRd) are the preferred first-line regimens for transplant-ineligible newly diagnosed multiple myeloma, but there is no head-to-head study comparing these regimens. This multicenter chart review compared the progression-free survival of DRd versus VRd as first-line therapy. DRd was associated with a significantly lower risk of disease progression or death compared to VRd. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 13, 2023 Category: Hematology Authors: Lucio Navarro Gordan, Carlyn Rose Tan, Robert Vescio, Jing Christine Ye, Carolina Schinke, Rohan Medhekar, Alex Z. Fu, Marie-H élène Lafeuille, Philippe Thompson-Leduc, Vipin Khare, John Reitan, Gary Milkovich, Shuchita Kaila, Faith Davies, Saad Z. Usma Tags: Original Study Source Type: research

Progression-Free Survival of Daratumumab vs. Bortezomib Triplet Combination with Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study
Multiple myeloma (MM) is a malignant neoplasm characterized by the presence of monoclonal immunoglobulins in blood and/or urine and the accumulation of plasma cells in the bone marrow 1. This can ultimately lead to end-organ damage including marrow failure, skeletal or bone lesions, renal failure, hypercalcemia, anemia, and infections 1. MM is the second most common hematologic malignancy in the United States (US), with 35,730 expected new cases and 12,590 deaths in 2023 1, 2. Two thirds of patients with newly diagnosed MM (NDMM) are aged over 65 years (median age at diagnosis is 69) and the median age at death is 75 years...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 13, 2023 Category: Hematology Authors: Lucio Gordan, Carlyn Rose Tan, Robert Vescio, Jing Christine Ye, Carolina Schinke, Rohan Medhekar, Alex Z. Fu, Marie-H élène Lafeuille, Philippe Thompson-Leduc, Vipin Khare, John Reitan, Gary Milkovich, Shuchita Kaila, Faith Davies, Saad Z. Usmani Tags: Original Study Source Type: research

Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma – The Oregon Health and Science University Experience
Peripheral T-cell lymphomas (PTCL) are a group of aggressive malignancies with inferior outcomes compared to B-cell non-Hodgkin lymphoma (NHL). Both allogeneic and autologous hematopoietic cell transplantation (HCT) are commonly employed for consolidation and salvage. We conducted a single-center review of all adult PTCL patients at OHSU who received HCT from 1991 to 2020 with responses assed by CIBMTR criteria. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 11, 2023 Category: Hematology Authors: Derek Galligan, Staci Williamson, Jessie Myers, Andy I Chen, Brandon Hayes-Lattin, Craig Okada, Stephen Spurgeon, Richard Maziarz, Levanto Schachter Tags: Original Study Source Type: research

Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients with Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data from a Randomized Controlled Phase 2 Study to Facilitate Optimal Treatment Experiences
Chlormethine (CL) gel was approved for treatment of mycosis fungoides based on the pivotal 201 trial (NCT00168064). Data visualization from individual patients is a powerful tool for discovery of hidden treatment trends. Here, we present a posthoc analysis of individual patient data from the pivotal trial to provide a more granular depiction of treatment and response changes over time, with an emphasis on end of treatment status. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 7, 2023 Category: Hematology Authors: Larisa J. Geskin, James T. Angello, Martine Bagot, Emmanuella Guenova, Neda Nikbakht, Christiane Querfeld, Julia J. Scarisbrick Tags: Original Study Source Type: research

Treatment patterns and outcomes in U.S. military veterans diagnosed with chronic lymphocytic leukemia (CLL)
U.S. veterans in the Veterans Affairs (VA) Healthcare System are managed in a national single-payer system with access to FDA-approved therapies. Prescribing patterns and outcomes of patients with CLL manage in the VA system are described. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 7, 2023 Category: Hematology Authors: Helen Ma, Susan O'Brien, Pankaj Gupta Source Type: research

Early T-cell Precursor Leukemia: a High-Risk subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan
Early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL/LBL) is a newly recognized entity of T-lymphoblastic leukemia/lymphoma. The optimal therapeutic approaches to adult patients are poorly studied. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 5, 2023 Category: Hematology Authors: Khalid Halahleh, Isra Muradi, Mohammad Zakaria Khalil, Lina Halahleh, Maher Sughayer, Nazmi Kamal, Iyad Sultan, Kamal Alrabi Tags: Original Study Source Type: research

Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden Hospital
Chemotherapy followed by consolidative mediastinal radiotherapy has been the standard treatment for primary mediastinal B cell lymphoma; however, there are long-term side effects associated with radiotherapy. We retrospectively reviewed outcomes of patients treated at our institution using a PET-guided approach that identified patients suitable for surveillance rather than radiotherapy following chemotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 29, 2023 Category: Hematology Authors: Su Li, Bhupinder Sharma, Siraj Yusuf, Vasiliki Michalarea, Mary Gleeson, Laura Hickmott, Andrew Wotherspoon, Ayoma D. Attygalle, Katherine Vroobel, Simon O'Connor, Yong Du, Andrea Kuhnl, Sunil Iyengar, Dima El-Sharkawi, Ian Chau, David Cunningham Tags: Original Study Source Type: research

Outcomes of patients treated with RCHOP with a PET adapted approach for consolidative radiotherapy: a retrospective single centre study at the Royal Marsden hospital
Treatment with CHOP based chemotherapy with consolidative radiotherapy (CRT) for primary mediastinal B cell lymphoma (PMBCL) has been the standard approach in the pre rituximab era. Overtreatment with CRT for patients who may have already been cured by primary immunochemotherapy in the Rituximab era is a significant concern due to the long term toxicity associated with radiotherapy. Positron emission tomography (PET) may help to identify patients who may not benefit from further CRT. We conducted a retrospective review of patients treated at the Royal Marsden hospital between 2003-2020 for PMBCL to assess CRT use and survi...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 29, 2023 Category: Hematology Authors: Su Li, Bhupinder Sharma, Siraj Yusuf, Vasiliki Michalarea, Mary Gleeson, Laura Hickmott, Andrew Wotherspoon, Ayoma D. Attygalle, Katherine Vroobel, Simon O'Connor, Yong Du, Andrea Kuhnl, Sunil Iyengar, Dima El-Sharkawi, Ian Chau, David Cunningham Tags: Original Study Source Type: research

Association of selinexor dose reductions with clinical outcomes in the BOSTON study
Dose modifications in response to adverse events (AEs) can maintain tumor response and improve therapy tolerability. We conducted a post-hoc analysis of the efficacy and safety of reduced selinexor doses in the BOSTON trial (NCT03110562). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 28, 2023 Category: Hematology Authors: Sundar Jagannath, Sosana Delimpasi, Sebastian Grosicki, Dane R. Van Domelen, Ohad S. Bentur, Ivan Špička, Meletios A. Dimopoulos Tags: Original Study Source Type: research

Multiple Myeloma in Young Patients: A Scoping Review
Data on the disease course, presenting features, outcomes, and prognosis of younger patients with multiple myeloma (MM) is lacking. Younger patients with MM have historically been considered to have better outcomes primarily based on better tolerance of treatment and lack of medical comorbidities, but the specific age range of this population has not been uniformly defined. Given the lack of consistent data reporting in patients considered to be young MM patients, we performed a Scoping Review to highlight the research currently available to start drawing conclusions about these patients and highlight unmet areas of need t...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 27, 2023 Category: Hematology Authors: Mary Steinbach, Karun Neupane, Muhammad Aziz, Wade Lee-Smith, Kelley Julian, Amandeep Godara, Brian McClune, Amar H. Kelkar, Douglas Sborov, Ghulam Rehman Mohyuddin Tags: Review Article Source Type: research

Significance of alkaline phosphatase after chimeric antigen receptor T cell therapy in multiple myeloma
This study examined the significance of alkaline phosphatase (ALP) after CAR-T therapy in patients with relapsed/refractory multiple myeloma (MM). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 27, 2023 Category: Hematology Authors: Rujiao Dong, Yudi Wang, Xiaohong Sun, Yuanyuan Lin, Yuqing Luo, Chongyun Xing, Lan Sun, Shenghui Zhang, Kang Yu, Songfu Jiang, Yi Chen Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 25, 2023 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 25, 2023 Category: Hematology Source Type: research

Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
Patients with prior allogeneic stem cell transplant (alloSCT) are typically excluded from trials of chimeric antigen receptor (CAR) T cell therapies, because their engineered cells may include allogeneic T cells. Ciltacabtagene autoleucel (cilta-cel) demonstrated early, deep, durable responses and manageable safety in heavily pretreated relapsed/refractory multiple myeloma patients. We retrospectively analyzed patients who received alloSCT prior to cilta-cel in CARTITUDE-1. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 22, 2023 Category: Hematology Authors: Myo Htut, Binod Dhakal, Adam D. Cohen, Thomas Martin, Jesus G Berdeja, Saad Z. Usmani, Mounzer Agha, Carolyn C. Jackson, Deepu Madduri, William Deraedt, Enrique Zudaire, Tzu-min Yeh, Xiaoying Xu, Lida Pacaud, Muhammad Akram, Sundar Jagannath Tags: Original Study Source Type: research